On June 16, 2022, Fang, Wenkui; Li, Guanqun; Cai, Yuting; Pan, Xiang; Zhu, Wenhao; Wang, Yang; Wang, Zengquan published a patent.Electric Literature of 2092807-41-3 The title of the patent was Preparation of triazolopyrazine compound as Tyk2 specific inhibitor for prevention and/or treatment of autoimmune diseases and related inflammatory skin diseases. And the patent contained the following:
A triazolo pyrazine compound, wherein the triazolo pyrazine compound is a compound as represented by formula I as follows, or a stereoisomer, a geometrical isomer, a tautomer, a hydrate, a solvate, and a pharmaceutically acceptable salt or a prodrug thereof, wherein W is selected from a substituted or unsubstituted aryl or heteroaryl, X is C or N, and R is H or any substituent group. When the triazolo pyrazine compound provided by the invention is used as a Tyk2 specific inhibitor, a more targeted drug can be provided for autoimmune inflammatory diseases driven by an IL-23/Th17 axis, and the compound can be used for treating rheumatoid arthritis, psoriasis, ankylosing spondylitis, sicca syndrome, lupus erythematosus, inflammatory bowel disease, Behcet’s disease, severe COVID-19 pneumonia and other diseases more safely and effectively. The experimental process involved the reaction of 6,8-Dichloro-[1,2,4]triazolo[1,5-a]pyrazine(cas: 2092807-41-3).Electric Literature of 2092807-41-3
The Article related to triazolopyrazine compound preparation tyk2 inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Electric Literature of 2092807-41-3
Referemce:
1,2,3-Triazole – Wikipedia,
Triazoles – an overview | ScienceDirect Topics